




**balchem**<sup>®</sup>

Solve Today. Shape Tomorrow.



# Investor Presentation

## Q4 2023

# Safe Harbor Statement

---


- During the course of this presentation, management may make forward-looking statements regarding financial performance and future events.
- We will attempt to identify these statements by use of words such as expect, believe, anticipate, intend, and other words that denote future events. You should understand that, even though our forward-looking statements are based on assumptions we believe are reasonable when made, they are still subject to uncertainties that could cause actual results to differ materially from those in the forward-looking statements.
- We caution you to consider the important risk and other factors as set forth in the forward-looking statements section and in Item 1A risk factors in our Annual Reports on Form 10-K as filed with the U.S. Securities and Exchange Commission that could cause actual results to differ from those in the forward-looking statements as contained in this presentation.
- Forward-looking statements made herein are summaries of previous public disclosures, do not represent revised guidance, and we do not undertake to revise or update them from the date or dates of previous disclosure.
- In the case of any presentation delivered during the company's prescribed black-out periods, there will be no discussion or questions addressed regarding the current quarter's expected performance.

# Agenda

- **Balchem Overview**
- Vision and Strategic Focus
- Financial Performance & Capital Allocation
- Corporate Social Responsibility
- Wrap Up
- Appendix
  - GAAP to Non-GAAP reconciliations

# Balchem Corporation

Balchem develops, manufactures, and markets specialty ingredients that help make the world a healthier place



## At a Glance

- Founded in 1967
- NASDAQ: BCPC
- Approximately 1,300 Employees
- 2023 Revenue: \$922 Million

## Three Business Segments – 2023 Revenue



# Executive Leadership

---



## Ted Harris | Chairman, President, and CEO

- Joined Balchem in May 2015
- Prior to Balchem was a Senior VP of Ashland Inc. where he held a series of senior leadership roles over 10+ years
- Independent director and member of the Board of Directors of Pentair plc.
- MBA from Harvard University and bachelor's degree from Lehigh University in chemical engineering

## Martin Bengtsson | CFO

- Joined Balchem in February 2019
- Prior to Balchem had a 15-year career at Honeywell and most recently was CFO for the \$11B Performance Materials & Technologies segment
- Bachelor's degree from Northwestern University in economics and began career as Senior Auditor for Deloitte




# Balchem's Value Proposition

## Value to our Customers

- High efficacy nutrients essential for life
- Enhanced animal health and feed productivity
- Functional ingredient systems formulations and application expertise
- Crop protection and yield improvement
- Complete supply chain capabilities and assurance


## Value to society

- Increased health and well-being of humans and animals
- Enhanced food chain productivity to give a growing population sustainable access to food



# Segment Overview

## Leveraging Solutions Across Segments



Segment	Markets Served	Solutions
Human Nutrition & Health	<ul style="list-style-type: none"> <li>• Nutritional Supplements</li> <li>• Food and Beverage</li> <li>• Infant &amp; Toddler Formula</li> <li>• Organic Cereal</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Microencapsulation</b></li> <li>• <b>Choline</b>, &amp; Vitamin K2</li> <li>• <b>Chelated Minerals</b></li> <li>• Powder, Flavor, &amp; Cereal Systems</li> </ul>
Animal Nutrition & Health	<ul style="list-style-type: none"> <li>• Dairy</li> <li>• Poultry and Swine</li> <li>• Companion Animal</li> <li>• Aquaculture</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Microencapsulation</b></li> <li>• <b>Choline</b></li> <li>• <b>Chelated Minerals</b></li> <li>• Amino Acids and Other Nutrients</li> </ul>
Specialty Products	<ul style="list-style-type: none"> <li>• Medical Device Sterilization</li> <li>• Nut and Spice Fumigation</li> <li>• Plant Nutrition</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Chelated Minerals</b></li> <li>• Performance Gases re-packaging and supply chain capabilities</li> </ul>
Other	<ul style="list-style-type: none"> <li>• Oil and Gas Fracking</li> <li>• Other Industrial Markets</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Choline</b></li> <li>• Choline Derivatives</li> </ul>

# Agenda

- Balchem Overview
- **Vision and Strategic Focus**
- Financial Performance & Capital Allocation
- Corporate Social Responsibility
- Wrap Up
- Appendix
  - GAAP to Non-GAAP reconciliation

# Our vision

is clear – to make the world a healthier place.

# Our mission

is focused – to build a global nutrition and health company delivering trusted, innovative and science-based solutions to our customers.


## Our Core Values



Always doing the **right** thing



Thinking **big** and acting small



Collaborating and growing **together**



Playing to **win**



Staying focused on the **customer**

# How Do We Make the World a Healthier Place?

Improve nutrient bioavailability for animals, reducing feed inputs and land required to produce high quality animal protein

Help farmers grow crops that are harder when faced with stressors like disease and pests

Provide food, beverage, and dietary supplement ingredients that support cognitive, emotional, and physical well-being across generations

Power the day with plant & animal proteins, healthy fats, minerals, nutrients, and specialty nutraceuticals

Support prenatal, infant and toddler health with targeted nutritional ingredients

Create higher yields and higher quality crops with fewer inputs.

Improve nutrient bioavailability to reduce animal waste excreted into the environment

Decrease food waste from farm to table via natural technologies

Provide nutritious foods for companion animals

Provide products and services to medical device sterilizers



# Strategic Focus

---

- **Strengthening Positions in Attractive, Growing Markets**
  - Building scale, adding adjacent capabilities, expanding market and geographic reach, broadening our portfolio of solutions, investing in new science, enabling market awareness
- **Driving Organic Growth**
  - Creating new demand through innovation, market penetration, new product launches, geographic expansion, and expanding addressable markets
- **Strategic M&A**
  - Augment organic growth and accelerate strategic initiatives
- **Excellence in Execution**
  - Maintaining a strong margin profile, efficient cash flow conversion, and a solid balance sheet

# Growth Platforms

## Multiple platforms to drive growth

### Human Nutrition & Health


- Realize Choline and Vitamin K2 market potential
- Transition from low to high bioavailable Mineral Nutrition
- Systems for Nutritional Beverages
- Microencapsulation for food safety and preservation
- Geographic expansion and M&A

### Animal Nutrition & Health

- Rumen-protected nutrients for Dairy
- Reashure<sup>®</sup> penetration
- Next generation rumen by-pass and release technology
- Pet and aquaculture expansion
- Geographic expansion and M&A

### Specialty Products

- Plant micronutrients penetration and application
- Leveraging Global Performance Gases platform
- Geographic expansion and M&A



# Agenda

- Balchem Overview
- Vision and Strategic Focus
- **Financial Performance & Capital Allocation**
- Corporate Social Responsibility
- Wrap Up
- Appendix
  - GAAP to Non-GAAP reconciliation


# Q4 2023 Financial Summary

## Profitability growth and margin expansion

### Sales

(\$M)

↓ -1.6%




- Lower volumes partially offset by higher average selling prices

### Adj. EBITDA

(\$M)

↑ 5.4%




- Lower input costs and favorable portfolio mix driving higher margins

### Adj. Net Earnings

(\$M)

↑ 1.8%




- Growth in earnings partially offset by a higher tax rate in the quarter

### Adj. EPS

(\$/share)


↑ 1.6%



- Small increase in diluted outstanding shares (+0.2%)

# Full Year 2023 Financial Summary

## Strong Adj. EBITDA growth in a challenging environment



- Lower volumes partially offset by higher average selling prices





- Lower input costs and favorable portfolio mix driving higher margins

- Higher interest expenses on outstanding debt offset by growth in earnings

- Small increase in diluted outstanding shares (+0.2%)



# Historical Financials

## Consistent performance over the years



# Historical Financials

Solid contribution from all reporting segments over the years




# Balchem's Capital Allocation Strategy

## Capital allocation Priorities

- Support organic growth opportunities
- Augment growth with targeted M&A
- Diligent debt service
- Continue to pay and grow dividend
- Stock buy-backs for anti-dilution

## M&A


- Eight acquisitions since 2016
- Focus on nutrition and health
- Adding geographic reach and adjacent products/technologies, while consolidating markets



\* Trailing Twelve Months (TTM)

# Free Cash Flow Conversion

Translating profits into cash



# Recent Acquisitions

Augmenting organic growth with targeted acquisitions close to core

## Albion Minerals

- Adjacent product offering in high growth market
- Chelated Magnesium, Iron, Calcium, Zinc etc.

## Bioscreen

- Geographic expansion and processing technology
- Microencapsulation and Fermentation

## Kappa Bioscience

- Portfolio extension in high growth specialty vitamin market
- Vitamin K2 as MK-7

## Bergstrom Nutrition

- Portfolio extension in high growth specialty mineral market
- Specialty sulfur for supplements

2017

## Chol-Mix

- Geographic reach into Europe
- Dry Choline Chloride

## IFP

- Market consolidation and processing technology
- Microencapsulation and Agglomeration

2019

## Chemogas

- Geographic expansion of market leadership to Europe
- Performance gas solutions

## Zumbro River Brand

- Consolidation and portfolio extension
- High protein extrusion and agglomeration

2018


2022

2016

# Dividends

## Consistent dividend policy

- Annual double-digit dividend growth for the last decade
- Consistency in execution



# Agenda

- Balchem Overview
- Vision and Strategic Focus
- Financial Performance & Capital Allocation
- **Corporate Social Responsibility**
- Wrap Up
- Appendix
  - GAAP to Non-GAAP reconciliation

# Sustainability at Balchem

## Our Sustainability Objectives & Framework

Provide innovative solutions for the health & nutritional needs of the world.

**Company**



People



Planet



Profit

**Culture**

Operate with excellence as strong stewards of our employees, customers, shareholders & communities

# Making the world a healthier place

**1.4 billion**  
people reached  
in 2022

The total number of people impacted is calculated by measuring the annual consumption of protein and the daily recommended doses of minerals, essential nutrients and vitamins.

# Sustainability At Balchem

## Supporting a future for all


- As a signatory to the United Nations (UN) Global Compact, Balchem supports the Ten Global Principles in the areas of human rights, labor, environment and anti-corruption.
- We are committed to advancing the broad goals of the UN across our areas of influence.

Balchem was named one of **America's Most Responsible Companies** by Newsweek magazine for the fourth consecutive year.



# Our 2030 Sustainability Goals and Priorities

## 2030 Sustainability Goals



Balchem commits to reducing our GHG emissions use by **25%**



Balchem commits to reducing our global water use by **25%**

## Our Priority Sustainable Development Goals



Learn more about our sustainability programs



# Agenda

- Balchem Overview
- Vision and Strategic Focus
- Financial Performance & Capital Allocation
- Corporate Social Responsibility
- **Wrap Up**
- Appendix
  - GAAP to Non-GAAP reconciliation

# Balchem

---

A global nutrition and health company delivering trusted, innovative and science-based solutions to our customers

- Leading positions in attractive markets
- Creating new demand through innovation
- Strong financial performance, delivering healthy margins and cash flows available for reinvestment
- Proven track record and well positioned for the future

# Agenda

- Balchem Overview
- Vision and Strategic Focus
- Financial Performance & Capital Allocation
- Corporate Social Responsibility
- Wrap Up
- **Appendix**
  - GAAP to Non-GAAP reconciliation

# Non-GAAP Financial Information

---

## **Non-GAAP Financial Information**

In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted per diluted share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, and free cash flow. The non-GAAP financial measures disclosed by the company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, nonqualified deferred compensation plan expense (income), and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the reconciliation tables below and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures.

# Non-GAAP Financial Information - Continued

Table 1

**Reconciliation of Non-GAAP Measures to GAAP**  
(Dollars in thousands, except per share data)  
(unaudited)

	Three Months Ended December 31,		Year Ended December 31,	
	2023	2022	2023	2022
<b>Reconciliation of adjusted gross margin</b>				
GAAP gross margin	\$ 74,993	\$ 68,639	\$ 302,056	\$ 280,451
Inventory valuation adjustment <sup>(1)</sup>	—	1,473	1,419	3,057
Amortization of intangible assets and finance lease <sup>(2)</sup>	665	712	2,683	2,025
Restructuring costs <sup>(3)</sup>	186	—	601	—
Adjusted gross margin	<u>\$ 75,844</u>	<u>\$ 70,824</u>	<u>\$ 306,759</u>	<u>\$ 285,533</u>
<b>Reconciliation of adjusted earnings from operations</b>				
GAAP earnings from operations	\$ 38,335	\$ 33,305	\$ 159,193	\$ 145,186
Inventory valuation adjustment <sup>(1)</sup>	—	1,473	1,419	3,057
Amortization of intangible assets and finance lease <sup>(2)</sup>	6,964	7,641	28,274	27,481
Restructuring costs <sup>(3)</sup>	186	—	8,365	—
Transaction and integration costs and unallocated legal fees <sup>(4)</sup>	(1,383)	293	(9,683)	3,109
Nonqualified deferred compensation plan expense (income) <sup>(5)</sup>	523	337	917	(401)
Adjusted earnings from operations	<u>\$ 44,625</u>	<u>\$ 43,049</u>	<u>\$ 188,485</u>	<u>\$ 178,432</u>
<b>Reconciliation of adjusted net earnings</b>				
GAAP net earnings	\$ 26,648	\$ 21,406	\$ 108,543	\$ 105,367
Inventory valuation adjustment <sup>(1)</sup>	—	1,473	1,419	3,057
Amortization of intangible assets and finance lease <sup>(2)</sup>	7,035	7,713	28,561	27,816
Restructuring costs <sup>(3)</sup>	186	—	8,365	—
Transaction and integration costs and unallocated legal fees <sup>(4)</sup>	(1,383)	293	(9,683)	3,109
Unrealized foreign currency loss on contingent consideration liability and net realized (gain) on foreign currency forward contracts <sup>(6)</sup>	—	2,015	—	(512)
Income tax adjustment <sup>(7)</sup>	(1,585)	(2,560)	(7,487)	(8,306)
Adjusted net earnings	<u>\$ 30,901</u>	<u>\$ 30,340</u>	<u>\$ 129,718</u>	<u>\$ 130,531</u>
Adjusted net earnings per common share - diluted	<u>\$ 0.95</u>	<u>\$ 0.94</u>	<u>\$ 4.00</u>	<u>\$ 4.03</u>

# Non-GAAP Financial Information - Continued

**Table 2**  
(unaudited)

	Three Months Ended December 31,		Year Ended December 31,	
	2023	2022	2023	2022
Net income - as reported	\$ 26,648	\$ 21,406	\$ 108,543	\$ 105,367
Add back:				
Provision for income taxes	6,619	4,370	28,718	28,382
Interest and other expenses	5,068	7,529	21,932	11,437
Depreciation and amortization	13,984	13,817	54,647	51,513
EBITDA	52,319	47,122	213,840	196,699
Add back certain items:				
Non-cash compensation expense related to equity awards	3,785	3,386	16,052	13,224
Inventory valuation adjustment <sup>(1)</sup>	—	1,473	1,419	3,057
Restructuring costs <sup>(3)</sup>	186	—	8,365	—
Transaction and integration costs and unallocated legal fees <sup>(4)</sup>	(1,383)	293	(9,683)	3,109
Nonqualified deferred compensation plan expense (income) <sup>(5)</sup>	523 -	337 -	917 -	(401)
Adjusted EBITDA	\$ 55,430	\$ 52,611	\$ 230,910	\$ 215,688

# Non-GAAP Financial Information - Continued

**Table 3**  
(unaudited)

	Three Months Ended December 31,			
	2023	Effective Tax Rate	2022	Effective Tax Rate
GAAP Income Tax Expense	\$ 6,619	19.9 %	\$ 4,370	17.0 %
Impact of ASU 2016-09 <sup>(8)</sup>	369		249	
Adjusted Income Tax Expense	\$ 6,988	21.0 %	\$ 4,619	17.9 %

	Year Ended December 31,			
	2023	Effective Tax Rate	2022	Effective Tax Rate
GAAP Income Tax Expense	\$ 28,718	20.9 %	\$ 28,382	21.2 %
Impact of ASU 2016-09 <sup>(8)</sup>	1,232		963	
Adjusted Income Tax Expense	\$ 29,950	21.8 %	\$ 29,345	21.9 %

**Table 4**  
(unaudited)

	Three Months Ended December 31,		Year Ended December 31,	
	2023	2022	2023	2022
Net cash provided by operating activities	\$ 67,406	\$ 41,655	\$ 183,761	\$ 138,536
Capital expenditures, proceeds from the sale of assets, settlement of net investment hedge, and capitalized ERP implementation costs	(11,441)	(14,136)	(32,653)	(49,157)
Free cash flow	\$ 55,965	\$ 27,519	\$ 151,108	\$ 89,379

# Non-GAAP Financial Information - Continued

(1) Inventory valuation adjustment: Business combination accounting principles require us to measure acquired inventory at fair value. The fair value of inventory reflects the acquired company's cost of manufacturing plus a portion of the expected profit margin. The non-GAAP adjustment to our cost of sales excludes the expected profit margin component that is recorded under business combination accounting principles. We believe the adjustment is useful to investors as an additional means to reflect cost of sales and gross margin trends of our business.

(2) Amortization of intangible assets and finance lease: Amortization of intangible assets and finance lease consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, other intangibles acquired primarily in connection with business combinations, an intangible asset in connection with a company-wide ERP system implementation, and one finance lease. We record expense relating to the amortization of these intangibles and finance lease in our GAAP financial statements. Amortization expenses for our intangible assets and finance lease are inconsistent in amount and are significantly impacted by the timing and valuation of an acquisition. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance.

(3) Restructuring costs: Expenses related to a reorganization of the business.

(4) Transaction and integration costs and unallocated legal fees: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. Unallocated legal fees for transaction-related non-compete agreement disputes are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with transactions that are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.

(5) Nonqualified deferred compensation plan (income) expense: Gains and losses on rabbi trust assets related to our nonqualified deferred compensation plan are recorded in other (income) expense while the offsetting increases or decreases to the deferred compensation liability are recorded within earnings from operations. The increases and decreases in the deferred compensation liability are driven by market volatility and are not a true reflection of company performance. We believe excluding these amounts from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount based on market conditions causing comparison of current and historical financial results to be difficult. Adjustments have been made to the prior period presentation to conform with the current period presentation.

(6) Unrealized foreign currency loss on contingent consideration liability and net realized (gain) on foreign currency exchange forward contracts: The unrealized foreign currency loss related to the contingent consideration liability recorded in connection with the Kappa acquisition and was recorded as other expense in our GAAP financial statements. The net realized gain on foreign currency exchange forward contracts related to four short-term foreign currency exchange forward contracts with JP Morgan Chase, N.A. in connection with the Kappa acquisition. These contracts did not qualify for hedge accounting and the net gain was recorded as other income in our GAAP financial statements. We believe that excluding these gains and losses from our Non-GAAP financial measures is useful to investors because such income or expense are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.

(7) Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting" and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate.

(8) Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), was the recognition during the three and twelve months ended December 31, 2023 and 2022, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities.



**balchem**<sup>®</sup>

Solve Today. Shape Tomorrow.

Thank you